Negative clinical trials in sarcoidosis: failed therapies or flawed study design?
نویسندگان
چکیده
منابع مشابه
Negative clinical trials in sarcoidosis: failed therapies or flawed study design?
In this issue of the European Respiratory Journal, JUDSON et al. [1] report the results of a large clinical trial involving two new potential therapies in sarcoidosis, a subcutaneous anti-tumour necrosis factor (TNF) agent, golimumab, and a novel anti-p40 (a component of both interleukin (IL)-12 and IL-23) agent, ustekinumab. The rationale for the use of anti-TNF agents in sarcoidosis is compel...
متن کاملClinical Trials Study Design
Observational Studies: Observational studies provide a mechanism for clarifying the epidemiology and risk factors/exposures that place populations at risk for disease. Observational studies assist in identifying clinical outcomes that might aid in predicting future disease. This type of study allows researchers to draw conclusions about responses to variables; they allow for associations but no...
متن کاملClinical trials of neuroprotective therapies.
There have been numerous failures in the field of acute stroke therapy over many years, but the first large clinical trial showing preliminary indications of efficacy and safety of a neuroprotective drug, NXY-059, has now been fully reported. If confirmed, it will mean that a second therapy for acute stroke has been identified and neuroprotective drug development as a class can proceed. Additio...
متن کاملTrustworthy or flawed clinical prediction rule?
We read with interest the recently published paper by Hilder et al. [1], where the authors present the PRESET-Score, a new clinical prediction rule for patients with acute respiratory distress syndrome treated with extracorporeal membrane oxygenation (ECMO). While the topic is clinically relevant and interesting, we are worried that spurious findings, biased results, and overstated findings are...
متن کاملEndpoints for clinical trials of sarcoidosis.
Over the past few years an increasing number of prospective controlled sarcoidosis treatment trials have been completed. Unfortunately, these studies utilize different endpoints making comparisons between studies difficult. At the recent World Association of Sarcoidosis and other Granulomatous disease (WASOG) meeting, a session was dedicated to the evaluation of clinical endpoints for various d...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Respiratory Journal
سال: 2014
ISSN: 0903-1936,1399-3003
DOI: 10.1183/09031936.00156314